Back to Companies
Enliven Therapeutics, Inc.
ELVNNasdaqCIK: 0001672619
Over the 50 most recent insider filings, Enliven Therapeutics, Inc. (ELVN) has seen activity from 14 distinct insiders — all of them on the sell side. The activity is heavily weighted toward selling: $0 bought versus $64.2M sold, net sales of $64.2M. ORBIMED ADVISORS LLC (10% Owner) is the most active by dollar volume, and the single largest transaction was $39.0M by ORBIMED ADVISORS LLC. All figures are drawn from official SEC Form 3, 4, and 5 disclosures and update as new filings arrive.
Total Volume
$100.1M
Purchases
$0
Sales
$64.2M
Unique Insiders
14
Recent Insider Trades
50 loaded
| Jul 21 | ELVN Enliven Therapeutics, Inc. | Hohl Benjamin | Insider | Sell | $316.8K |
| Jul 21 | ELVN Enliven Therapeutics, Inc. | Collins Helen Louise | Insider | Sell | $263.4K |
| Jun 24 | ELVN Enliven Therapeutics, Inc. | ORBIMED ADVISORS LLC | 10% Owner | Sell | $39.0M |
| Jun 22 | ELVN Enliven Therapeutics, Inc. | Collins Helen Louise | Insider | Sell | $219.0K |
| Jun 22 | ELVN Enliven Therapeutics, Inc. | Hohl Benjamin | Insider | Sell | $263.6K |
| Jun 17 | ELVN Enliven Therapeutics, Inc. | ORBIMED ADVISORS LLC | 10% Owner | Sell | $12.7M |
| Jun 9 | ELVN Enliven Therapeutics, Inc. | Kunkel Lori Anne | Insider | Sell | $345.4K |
| May 20 | ELVN Enliven Therapeutics, Inc. | Collins Helen Louise | Insider | Sell | $199.0K |
| Apr 21 | ELVN Enliven Therapeutics, Inc. | Collins Helen Louise | Insider | Sell | $238.4K |
| Mar 27 | ELVN Enliven Therapeutics, Inc. | Collins Helen Louise | Insider | Sell | $1.4M |
| Mar 19 | ELVN Enliven Therapeutics, Inc. | Collins Helen Louise | Insider | Sell | $138.8K |
| Feb 19 | ELVN Enliven Therapeutics, Inc. | Heyman Richard A. | Insider | Sell | $32.2K |
| Feb 19 | ELVN Enliven Therapeutics, Inc. | Collins Helen Louise | Insider | Sell | $1.2M |
| Feb 17 | ELVN Enliven Therapeutics, Inc. | Hohl Benjamin | Insider | Grant | $4.1M |
| Feb 17 | ELVN Enliven Therapeutics, Inc. | Ballal Rahul D. | Insider | Award | $465.1K |
| Feb 17 | ELVN Enliven Therapeutics, Inc. | Derynck Mika K | Insider | Award | $465.1K |
| Feb 17 | ELVN Enliven Therapeutics, Inc. | Heyman Richard A. | Insider | Award | $522.4K |
| Feb 17 | ELVN Enliven Therapeutics, Inc. | Bauer Jake | Insider | Award | $465.1K |
| Feb 17 | ELVN Enliven Therapeutics, Inc. | Gupta Rishi | Insider | Award | $966.1K |
| Feb 17 | ELVN Enliven Therapeutics, Inc. | Garland J. Scott | Insider | Award | $38.8K |
| Feb 17 | ELVN Enliven Therapeutics, Inc. | Kunkel Lori Anne | Insider | Award | $465.1K |
| Feb 17 | ELVN Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Insider | Grant | $3.1M |
| Feb 17 | ELVN Enliven Therapeutics, Inc. | Patel Anish | Insider | Grant | $3.3M |
| Feb 17 | ELVN Enliven Therapeutics, Inc. | Collins Helen Louise | Insider | Grant | $4.1M |
| Feb 10 | ELVN Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Insider | Sell | $145.2K |
| Jan 22 | ELVN Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Insider | Sell | $535.1K |
| Jan 22 | ELVN Enliven Therapeutics, Inc. | Heyman Richard A. | Insider | Sell | $32.9K |
| Jan 13 | ELVN Enliven Therapeutics, Inc. | Patel Anish | Insider | Sell | $1.4M |
| Jan 12 | ELVN Enliven Therapeutics, Inc. | Heyman Richard A. | Insider | Sell | $348.3K |
| Jan 12 | ELVN Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Insider | Sell | $3.5M |
| Jan 9 | ELVN Enliven Therapeutics, Inc. | Garland J. Scott | Insider | Other | $0 |
| Jan 9 | ELVN Enliven Therapeutics, Inc. | Garland J. Scott | Insider | Award | $918.5K |
| Dec 23 | ELVN Enliven Therapeutics, Inc. | Hohl Benjamin | Insider | Exercise | $64.5K |
| Dec 23 | ELVN Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Insider | Sell | $84.2K |
| Dec 19 | ELVN Enliven Therapeutics, Inc. | Kunkel Lori Anne | Insider | Exercise | $35.7K |
| Dec 12 | ELVN Enliven Therapeutics, Inc. | Fair Richard A. | Insider | Other | $0 |
| Dec 12 | ELVN Enliven Therapeutics, Inc. | Fair Richard A. | Insider | Award | $16.4M |
| Dec 10 | ELVN Enliven Therapeutics, Inc. | Patel Anish | Insider | Sell | $140.1K |
| Nov 21 | ELVN Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Insider | Sell | $279.2K |
| Nov 19 | ELVN Enliven Therapeutics, Inc. | Kintz Samuel | Insider | Sell | $272.7K |
| Nov 12 | ELVN Enliven Therapeutics, Inc. | Patel Anish | Insider | Sell | $116.0K |
| Oct 22 | ELVN Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Insider | Sell | $276.0K |
| Oct 21 | ELVN Enliven Therapeutics, Inc. | Kintz Samuel | Insider | Sell | $266.7K |
| Oct 9 | ELVN Enliven Therapeutics, Inc. | Patel Anish | Insider | Sell | $134.0K |
| Oct 1 | ELVN Enliven Therapeutics, Inc. | Hohl Benjamin | Insider | Sell | $66.3K |
| Sep 30 | ELVN Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Insider | Sell | $81.0K |
| Sep 30 | ELVN Enliven Therapeutics, Inc. | Kintz Samuel | Insider | Sell | $74.2K |
| Sep 25 | ELVN Enliven Therapeutics, Inc. | Kintz Samuel | Insider | Sell | $56.1K |
| Sep 25 | ELVN Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Insider | Sell | $30.0K |
| Sep 23 | ELVN Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Insider | Sell | $135.7K |
50 filings+